Fortune December 28, 2023
Amanda Seitz, The Associated Press

New obesity drugs are showing promising results in helping some people shed pounds but the injections will remain out of reach for millions of older Americans because Medicare is forbidden to cover such medications.

Drugmakers and a wide-ranging and growing bipartisan coalition of lawmakers are gearing up to push for that to change next year.

As obesity rates rise among older adults, some lawmakers say the United States cannot afford to keep a decades-old law that prohibits Medicare from paying for new weight loss drugs, including Wegovy and Zepbound. But research shows the initial price tag of covering those drugs is so steep it could drain Medicare’s already shaky bank account.

A look at the debate around if — and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Insurance, Medicare, Patient / Consumer, Pharma, Pharma / Biotech, Provider
Shifting Our Healthcare Delivery Model from Reactive to Proactive
Medtronic, Tempus testing AI to find potential TAVR patients
Why Tufts Medicine ended its hospital-at-home program
How the Triadic Model of Interpreter, Patient and Provider has Elevated Healthcare Communications
Is a lack of understanding driving alcohol-related deaths in the U.S.?

Share This Article